Hes said his clinical team has put many thousands of patients on BPC-157 without a single adverse event

Some aspects of the research appear promising, while others remain unproven: What appears promising so far: Reduced substance-seeking behavior observed in animal models Anecdotal and observational reports of decreased cravings in some individuals Growing scientific interest in shared reward pathways between appetite and addiction What remains unproven or unclear: Whether observed effects lead to sustained recovery outcomes How GLP-1s affect the psychological and social dimensions of addiction Whether benefits, if present, are consistent across substances or populations Differences in study design also limit interpretation: Animal trials do not reliably predict human outcomes Observational data cannot establish causation Controlled human trials remain small, limited, and inconsistent Safety considerations are equally important and must be weighed carefully: Common side effects include nausea, appetite suppression, and gastrointestinal distress Changes in appetite or weight may interact with existing mental health symptoms For individuals with eating disorders, appetite-suppressing effects may pose particular risks Given these uncertainties, GLP-1 medications should not replace evidence-based addiction treatments

How GLP-1 Users Can Meet Their Protein Needs Since traditional protein sources may become less appealing due to reduced appetite, GLP-1 users should focus on protein-rich foods that are easy to consume in smaller portions
Two interim analyses of OS were prespecified, with the first specified at the time of analysis of the primary end point.[32][Level of evidence B1] The median PFS was 9.9 months in patients who received the combination versus 6.2 months in patients treated with vemurafenib plus placebo
Each 30mL vial contains sterile water with 0.9% benzyl alcohol as a preservative, providing a stable, multi-use reconstitution medium trusted by research professionals